Karyopharm shares data at ash 2023 showing strong svr and tss durability observed from phase 1 study of selinexor 60mg and ruxolitinib in jak inhibitor (jaki)-naÏve myelofibrosis patients, with no svr or tss progressions observed as of the data cutoff(1)

Biomarker data from phase 1 study of selinexor in combination with ruxolitinib in treatment-naÏve myelofibrosis (mf) suggestive of disease modification data reinforce the potential for selinexor in combination with ruxolitinib to become a novel, first-line treatment for jaki-naÏve patients with mf newton, mass. , dec. 10, 2023 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced long-term follow up of treatment-naÏve patients with myelofibrosis (mf) who participated in the phase 1 portion of its study evaluating once-weekly selinexor in combination with ruxolitinib (nct04562389).
KPTI Ratings Summary
KPTI Quant Ranking